Other languages Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.19 ^USD	-3.92%		-3.33%	-35.56%

May. 06	Genenta Science S.p.A. Announces New Board Appointments	CI
Apr. 08	Genenta Science S.P.A. Announces Resignation of Board Members	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider	May. 06
Genenta Science S.p.A. Announces New Board Appointments	May. 06
Genenta Science S.P.A. Announces Resignation of Board Members	Apr. 08
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	Apr. 02
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	Feb. 08
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	Feb. 08
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors	Feb. 08
Sandoz to Acquire Cimerli Business from Coherus for $170 Million	Jan. 22
Genenta Science S p A : Consolidated Statements of Operations and Comprehensive Loss - Form 6-K	23-10-20
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-20
Genenta to Present at Upcoming Scientific and Investor Conferences	23-09-06
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	23-07-28
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	23-07-28
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	23-07-28
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma	23-06-29
Health Care Stocks Support American Depositary Receipts of European Equities	23-06-16
Genenta to Provide Update on Lead Product Temferon™	23-05-16
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	23-05-10
Genenta Science S p A : Effectiveness of the Amended and Restated OSR License Agreement - Form 6-K	23-05-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Other languages

Filters